Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuances
Ratios

Aytu Biopharma (AYTU) Shares Outstanding (2016 - 2026)

Aytu Biopharma has reported Shares Outstanding over the past 15 years, most recently at $10.7 million for Q4 2025.

  • Quarterly Shares Outstanding rose 73.97% to $10.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.7 million through Dec 2025, up 73.97% year-over-year, with the annual reading at $9.0 million for FY2025, 50.3% up from the prior year.
  • Shares Outstanding was $10.7 million for Q4 2025 at Aytu Biopharma, up from $9.9 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $10.7 million in Q4 2025 and troughed at $1.4 million in Q2 2021.
  • The 5-year median for Shares Outstanding is $5.5 million (2023), against an average of $5.0 million.
  • Year-over-year, Shares Outstanding crashed 91.61% in 2021 and then skyrocketed 186.02% in 2023.
  • A 5-year view of Shares Outstanding shows it stood at $1.5 million in 2021, then surged by 125.46% to $3.4 million in 2022, then soared by 64.56% to $5.6 million in 2023, then increased by 10.82% to $6.2 million in 2024, then surged by 73.97% to $10.7 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Shares Outstanding are $10.7 million (Q4 2025), $9.9 million (Q3 2025), and $9.0 million (Q2 2025).